News ListThursday March 04, 2010 Ipsogen appoints Corinne Danan as Vice President Commercial OperationsIPSOGEN announces today that Corinne Danan has joined the company as Vice President Commercial Operations to develop Ipsogen presence in Europe and rest of the world.More Category: Corporate
 Wednesday February 17, 2010 2009 revenue totaled €6.7 millionUp 63% on the previous financial year and up 60% at constant forex Category: Investors
 Monday January 25, 2010 IPSOGEN Obtains Option to Acquire License on TET2 abnormalities to improve the Diagnosis of Blood-based DisordersIPSOGEN today announces the signature of an option agreement for the worldwide and exclusive license on genomic abnormalities in the TET2 gene. The scientific corpus supporting these TET2 patent rights has been developed by a... Category: Leukemia
 Monday January 11, 2010 The Institut Curie and IPSOGEN sign a scientific collaboration agreement relating to the Genomic Grade, a molecular diagnostic tool for breast cancerParis, Marseille, January 11, 2010 - The INSTITUT CURIE and IPSOGEN (FR0010626028 - ALIPS) announce the signing of a scientific collaboration agreement in the breast cancer domain. Within the framework of this project, the... Category: Breast Cancer
 Thursday December 31, 2009 IPSOGEN to hold its Annual General Meeting of Shareholders on February 5, 2010, in Marseilles, FranceNotice of Meeting of this Shareholders’ AGM published in the French official legal bulletin (“BALO”). More Category: Investors
Monday December 21, 2009 Institut Paoli Calmettes and IPSOGEN presented a new study supporting the pivotal role of tumor grade in chemotherapy prescription at the 32nd Annual San Antonio Breast Cancer SymposiumThe study reinforces tumor grade as the most contributive factor for adjuvant chemotherapy in N-/M- IBC, together with tumor size Category: Breast Cancer
Tuesday December 08, 2009 IPSOGEN strengthens its Management and Board of DirectorsMarseille, 8th December 2009 - IPSOGEN (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company that develops, manufactures and markets tests for leukemia and breast cancer, today announces changes in its board and... Category: Corporate, Investors
Wednesday November 04, 2009 Scientific Publications: Standardised WT1 assay developed by the European LeukemiaNet (ELN) consortiumAn international collaborative study coordinated by the European Leukemia Network (ELN) consortium on standardisation of WT1 testing for risk stratification in Acute Myeloid Leukemia has been published in the November 2009 issue... Category: Leukemia
Monday November 02, 2009 Ipsogen expands its IVD offer in leukemia diagnostic with the CE marking of JAK2 MutaQuant™ and JAK2 MutaSearch™ KitsJAK2 MutaQuant™ and MutaSearch™ Kits are now CE marked! Category: Leukemia
Friday September 18, 2009 Results for the first half of 2009Buoyant growth in activity: +111% Another half of significant achievements: strengthening of the product portfolio and record sales growth in the United States Category: Investors
|
|
